Related Experiment Video

Updated: Jul 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Treatment of arterial hypertension in obese patients

Ulrich O Wenzel1, Christian Krebs

  • 1III Medizinische Klinik, Universitätsklinikum Hamburg Eppendorf, Hamburg, Germany.

Contributions to Nephrology
|August 25, 2006
PubMed

Insights

Obesity-related hypertension requires specific treatment. Angiotensin-converting enzyme (ACE) inhibitors or diuretics are recommended as first-line therapy due to their positive effects on insulin sensitivity and sodium retention in obese hypertensive patients.

Area of Science:

  • Cardiology
  • Metabolic Disorders
  • Pharmacology

Background:

  • Rising obesity rates correlate with increased hypertension prevalence.
  • Obesity-hypertension is linked to significant morbidity and mortality.
  • Current guidelines lack specific antihypertensive drug recommendations for obesity.

Purpose of the Study:

  • To provide evidence-based recommendations for antihypertensive drug selection in obese hypertensive patients.
  • To evaluate the metabolic and hemodynamic effects of various antihypertensive classes in obesity.
  • To address the gap in current clinical guidelines for managing obesity-related hypertension.

Main Methods:

  • Review of pathophysiological mechanisms linking obesity and hypertension.
  • Analysis of the effects of different antihypertensive drug classes on insulin sensitivity and lipid profiles.
  • Subjective criteria and pathophysiologic assumptions used to formulate recommendations.

Main Results:

  • Diuretics and beta-blockers may worsen insulin sensitivity and lipid levels.
  • Calcium antagonists are metabolically neutral.
  • ACE inhibitors and angiotensin receptor blockers improve insulin sensitivity and are beneficial in managing sodium retention characteristic of obesity-hypertension.

Conclusions:

  • ACE inhibitors and diuretics are recommended as first-line therapy for obesity-related hypertension.
  • Drug selection should consider the impact on metabolic and hemodynamic abnormalities.
  • Further research is needed to establish definitive guidelines for this patient population.

More Related Videos

An Acupoint Catgut-embedding Therapy for Treating Obesity04:50

An Acupoint Catgut-embedding Therapy for Treating Obesity

Published on: April 4, 2025

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.